Abstract Left ventricular (LV) remodeling and myocardial fibrosis have been linked to adverse heart failure outcomes. Mid wall late gadolinium enhancement (MW-LGE) on cardiac magnetic resonance (CMR) imaging is wellassociated with non-ischemic cardiomyopathy (NICM), but prevalence in ischemic cardiomyopathy (ICM) and association with remodeling are unknown. The population comprised patients with systolic dysfunction [LV ejection fraction (LVEF B 40 %)]. CMR was used to identify MW-LGE, conventionally defined as fibrosis of the mid-myocardial or epicardial aspect of the LV septum. 285 patients were studied. MW-LGE was present in 12 %, and was tenfold more common with NICM (32 %) versus ICM (3 %, p \ 0.001). However, owing to higher prevalence of ICM, 15 % of patients with MW-LGE had ICM. LV wall stress was higher (p = 0.02) among patients with, versus those without, MW-LGE despite similar systolic blood pressure (p = 0.24). In multivariate analysis, MW-LGE was associated with CMR-quantified LV end-diastolic volume (p = 0.03) independent of LVEF and mass. Incorporation of clinical and imaging variables demonstrated MW-LGE to be associated with higher LV enddiastolic volume (OR 1.13, CI 1.004-1.27 per 10 ml/m 2 , p = 0.04) after controlling for presence of NICM (OR 16.0, CI 5.8-44.1, p \ 0.001). While more common in NICM, MW-LGE can occur in ICM and is a marker of LV chamber dilation irrespective of cardiomyopathic etiology.
Introduction
Left ventricular (LV) chamber remodeling is an important prognostic marker that has been linked to heart failure and death [1] [2] [3] . Increased LV chamber size, an early adaptation to maintain cardiac output in the face of contractile dysfunction, can ultimately impair systolic function due to increased wall stress and altered myocardial architecture. Both LV chamber dilation and myocardial hypertrophy are associated with up-regulation of neurohormonal mediators [4-6], providing a physiologic mechanism for the relationship between pathologic remodeling and adverse prognosis. Consistent with this, LV remodeling parameters are established targets for heart failure therapies, with reverse remodeling shown to predict improved clinical outcomes [3, 7, 8] .
Myocardial tissue substrate holds the potential to impact LV remodeling. Cardiac magnetic resonance (CMR) tissue characterization imaging is widely used to assess myopathic substrate for both ischemic (ICM) and non-ischemic (NICM) cardiomyopathies. In patients with ICM, infarct burden is an established predictor of LV dilation and dysfunction [7, 9, 10] , as well as lack of LV remodeling response to heart failure medications [11] . CMR has also been used to demonstrate myocardial scar in the absence of coronary artery disease: NICM-associated scar; often termed mid wall late gadolinium enhancement (MW-LGE), characteristically involves the mid myocardial aspect of the interventricular septum [12, 13] . MW-LGE on CMR has been shown to correlate with actual fibrosis on histopathology [14, 15] and to predict increased longitudinal mortality risk [14, 16] . LV dysfunction and chamber dilatation have each been associated with MW-LGE [16] [17] [18] . However, although CMR can assess LV structure, function, and tissue characteristics within a single exam, the independent association of MW-LGE with LV remodeling parameters has not been tested. Additionally, while MW-LGE has been well described in NICM [13, 14, [16] [17] [18] , uncertainty exists as to whether it can occur in the context of angiographyclassified ICM.
This study examined prevalence and structural correlates of MW-LGE among a cross-sectional cohort of subjects with angiography-classified ICM and NICM. The goals were: (1) to determine the prevalence of MW-LGE among a broad population of patients with cardiomyopathy; and (2) to evaluate independent associations between MW-LGE and LV chamber remodeling.
Materials and methods

Population
The study population was retrospectively accrued from consecutive patients with CMR-evidenced advanced LV systolic dysfunction (LVEF B 40 %), in whom both blood pressure (BP) within 24 h of CMR (for assessment of wall stress) and clinical invasive X-ray angiography (for assignment of cardiomyopathic etiology) were available. In order to test associations between MW-LGE and LV remodeling, patients with conditions known to preclude assessment of localized fibrosis within the septal mid wall (i.e. amyloid, surgically repaired complex congenital heart disease, hypertrophic cardiomyopathy), or those with incomplete CMR exams (i.e. lack of delayed enhancement imaging necessary for MW-LGE) were excluded from this study.
CMR was performed at Weill Cornell Medical College (New York, NY) between May 2005 and November 2013. Transthoracic echocardiography (echo), if performed at Weill Cornell within 1 week of CMR, was used as a supplemental test for cardiac structure/function. Blood pressure was measured non-invasively as part of clinical care. Demographic indices were categorized using a standardized patient questionnaire, with results confirmed via review of medical records. In accordance with established criteria [19] , patients were classified as having ICM if obstructive coronary artery disease (C50 % left main, C70 % major epicardial vessel) was present on invasive angiography, or based on prior coronary revascularization. All other patients were classified as having NICM.
This study was conducted with approval of the Institutional Review Board (IRB) at Weill Cornell Medical College.
Imaging protocol
Cardiac magnetic resonance CMR was performed using 1.5 T scanners (General Electric, Waukesha, WI). Exams consisted of two components: (1) cine-CMR for geometry/function and (2) delayed enhancement (DE-) CMR for tissue characterization. Cine-CMR was performed using a steady-state free precession sequence. DE-CMR was performed 10-30 min after administration of gadolinium (0.2 mmol/kg) using a segmented inversion recovery sequence [20] , with inversion time tailored to null viable myocardium. Cine-and DE-CMR were obtained in matching short and long-axis planes: Short axis images were acquired throughout the LV from the mitral valve annulus through the apex. Long axis images were acquired in standard two-, three-and four-chamber orientations.
DE-CMR was used to identify MW-LGE, which was defined in accordance with established criteria as localized hyperenhancement within the mid myocardial aspect of the basal to mid inter-ventricular septum (Fig. 1) [13]. MW-LGE was scored as a binary variable (present/absent) and, if present, total MW-LGE size was quantified via planimetery of hyperenhanced myocardium. MI size was calculated as a percentage of LV myocardium based on transmurality of hyperenhanced myocardium on DE-CMR in accordance with established methods [21] .
Cine-CMR was used to assess cardiac function and chamber size. LV chamber volume at end-diastole and endsystole was quantified by planimetry of contiguous short axis images, with LV ejection fraction (LVEF) calculated based on chamber volumes. LV mass (myocardial volume 9 specific gravity) was measured at end-diastole; papillary muscle and trabeculae were included within myocardial contours [21, 22] with concentricity calculated as the ratio between mass and chamber volume. LV systolic wall stress (r) was calculated at peak systole based on myocardial volume (V MYO ), chamber volume (V LV ) and systolic BP [23] :
Echocardiography Transthoracic 2D echocardiograms were performed by experienced sonographers using commercially available equipment (i.e. General Electric Vivid-7, Philips IE 33).
Imaging was performed in parasternal long-and short-axis and apical 2-, 3-, and 4-chamber orientations. In accordance with American Society of Echocardiography guidelines for chamber quantification [24] , LV linear dimensions at end diastole and end systole were measured in the parasternal long axis at the level of the LV minor axis.
Statistical methods
Continuous variables (expressed as mean ± standard deviation) were compared using Student's t tests. Categorical variables were compared using v 2 or, when fewer than five expected outcomes per cell, Fisher's exact test. Clinical and imaging parameters were compared using bivariate correlation coefficients, as well as univariable and multivariable logistic regression analyses. Two-sided p \ 0.05 was considered indicative of statistical significance. Statistical calculations were performed using SPSS 20.0 (SPSS Inc, Chicago, IL).
Results
Population characteristics
The study population consisted of 285 patients with advanced LV dysfunction (mean LVEF 27 ± 8 %). Twothirds (68 %) had ICM based on invasive coronary angiography. Mean BP, as measured non-invasively within 1 day (4.7 ± 7 h) of CMR, was 118 ± 20/68 ± 13 mmHg. There was no difference in the prevalence of cardiovascular risk factors including diabetes and hypertension in relationship to MW-LGE presence (Table 1) . Whereas hypertension, diabetes mellitus and hyperlipidemia were each more common among patients with ICM as compared to NICM (all p \ 0.01), none of these risk factors modified the likelihood for MW-LGE within either cardiomyopathic category (p = NS for all).
MW-LGE was present in 12 % of the population; prevalence was over tenfold higher among patients with NICM as compared to ICM (32 vs. 3 %; p \ 0.001). However, owing to the predominance of ICM among the overall population, 15 % of cases with MW-LGE actually occurred in patients with obstructive CAD. Regarding infarction, among patients with coexistent angiography classified ICM and MW-LGE (n = 5), only three had evidence of MI by DE-CMR. Notably all of these patients had diffuse global hypokinesis on cine-CMR. In addition, nearly a fourth of patients with MW-LGE (21 %; n = 7) had concomitant ischemic pattern MI on DE-CMR. MI size on DE-CMR was similar between patients with only MI versus those with concomitant MI and MW-LGE (p = 0.55). Figure 1b provides a representative example of MW-LGE in a patient with angiography-classified ICM.
Cardiac function and remodeling Table 2 reports cardiac function and remodeling indices in relation to MW-LGE. As shown, MW-LGE was associated with increased LV chamber size and wall stress (both p \ 0.05). Among wall stress components, only chamber volume and myocardial mass differed between patients with and without with MW-LGE, whereas systolic BP was similar between groups (p = NS). Regarding systolic function, Table 2 demonstrates that MW-LGE-associated decrement in CMR quantified LVEF (p = 0.02) was not associated with reduction in either stroke volume (p = 0.22) or cardiac output (p = 0.09), consistent with the concept that end-diastolic chamber dilation was a compensation for lower systolic function. (Table 3A) demonstrated LV end diastolic volume be independently associated with MW-LGE (OR 1.14, CI 1.02-1.29; p \ 0.05) after controlling for LV ejection fraction (OR 0.84, CI 0.50-1.42; p = 0.51) and myocardial mass (OR 0.99, CI 0.84-1.17; p = 0.90). Analysis of clinical variables (Table 3B ) confirmed a strong association of MW-LGE with NICM (OR 17.8, CI 6.3-50.3; p \ 0.001), which was independent of age and clinical indices. As shown in Table 3C , a combined model incorporating both clinical and imaging variables demonstrated both NICM and LV chamber volume to be independently associated with MW-LGE even after controlling for LV ejection fraction. Overall strength (v 2 = 52.5; p \ 0.001) of the combined clinical/imaging model for MW-LGE was higher than that of isolated clinical (v 2 = 48.0; p \ 0.001) and CMR imaging (v 2 = 11.8; p = 0.008) models.
Prevalence and size of mid-wall fibrosis in relation to LV volume Figure 2 reports MW-LGE prevalence in relation to population-based stratification of LV chamber volume (Fig. 2a) and wall stress (Fig. 2b) . As shown, MW-LGE was fourfold more common among patients in the highest, as compared to those in the lowest tertile of LV end diastolic volume (7.7 vs. 1.8 %), paralleling a twofold difference in MW-LGE prevalence among groups stratified based on LV wall stress (6.3 vs. 2.8 %).
MW-LGE constituted, on average, 1.9 ± 1.4 (range 0.1-4.8) grams, corresponding to 0.9 ± 0.7 % (0.05-2.9 %) LV myocardium. Figure 3 illustrates the relationship between MW-LGE size and LV chamber volume, with MW-LGE-affected patients partitioned into two groups based on fibrosis size. As shown, LV volume was similar 
Discussion
This study highlights the importance of myocardial tissue characterization for cardiomyopathy assessment: Among a broad cohort of patients with advanced LV dysfunction, 12 % had MW-LGE by CMR. Whereas MW-LGE was far more common among patients with angiography-classified NICM (32 %), this association was not exclusive, with MW-LGE present in a small percentage (3 %) of patients with ICM. MW-LGE was strongly associated with LV chamber dilation by both CMR and echo, with multivariate analysis demonstrating an independent association between presence of MW-LGE and magnitude of LV chamber dilation even after controlling for cardiomyopathy etiology and severity of contractile dysfunction. Our study demonstrates that MW-LGE is associated with increased chamber size by two independent modalities-CMR and echo. CMR provides geometry independent assessment of LV chamber quantification and can simultaneously also evaluate myocardial tissue substrate (i.e. MW-LGE). On the other hand, in clinical practice, echo is widely used as the primary screening test for LV geometry and has been used for this purpose in multiple large scale population-based studies [2, 7, 26]. Importantly, echo based measurements of LV chamber size have been shown to predict long-term adverse outcomes [26] , as has MW-LGE by DE-CMR [14] . Applied clinically, this association suggests that patients with LV chamber dilation whether identified by CMR or echo are at increased risk for MW-LGE and its associated adverse clinical and remodeling sequalae.
Our observation that MW-LGE can occur in the context of ICM sheds new light on earlier CMR literature, which suggested that this pattern of fibrosis is exclusively found among patients with NICM. For example, among a cohort of 90 cardiomyopathy patients, McCrohon et al. [13] Prevalence of MW-LGE in relation to population-based tertiles of LV end-diastolic volume (a) and wall stress (b). As shown, MW-LGE prevalence increased stepwise in relation to both LV remodeling parameters (both p \ 0.05), although magnitude of difference between highest and lowest tertiles were greater for LV volume than for the aggregate parameter of LV wall stress Fig. 3 Mid-wall fibrosis size in relation to LV remodeling. LV enddiastolic volume (mean ± SD) among patients without MW-LGE (black bar), as well as MW-LGE-affected patients (grey bars) stratified into two groups based on fibrosis size (right = top, left = bottom 50 %). Note that both groups of MW-LGE-affected patients had larger LV chamber volumes than did those without MW-LGE, with non-significant differences between MW-LGE-affected patients stratified by fibrosis size reported that no patients with ICM had MW-LGE. Our results, derived from a larger cohort, demonstrate that MW-LGE can occur in the setting of ICM as classified based on invasive coronary angiography. Consistent with the known higher prevalence of ICM as compared to NICM [26] , 15 % of patients with MW-LGE in our study population had obstructive CAD. The notion that myocardial and coronary substrate can differ is well established. Endomyocardial biopsy studies have shown histologic findings consistent with myocarditis in heart failure patients with angiography-evidenced CAD [27] . Autopsy studies have demonstrated that pathology evidenced ischemic type scar can occur in the absence of obstructive CAD [28, 29] . Our findings demonstrate the converse-namely that non-ischemic scar can be present among patients with angiography evidenced CAD. It is possible that MW-LGE in patients with angiographic CAD may represent a mixed cardiomyopathic process (i.e. nonischemic myopathic insults from concomitant with angiographic CAD). Further studies using histopathology analysis maybe warranted to further investigate this issue. Our findings also extend upon prior research that has linked MW-LGE to LV remodeling [14, 17, 18] . Consistent with our results, studies have reported higher LV chamber size and myocardial mass, as well as lower EF among patients with MW-LGE [14, 17] . Higher LV wall stress-a measure of myocardial load directly proportional to chamber volume and BP, and inversely proportional to myocardial mass-has also been shown to be associated with MW-LGE [23] . However, to the best of our knowledge, no study has simultaneously tested the independent relationship between MW-LGE and LV remodeling indices, raising uncertainty as to whether MW-LGE is primarily associated with alterations in LV volume, myocardial geometry, or contractile dysfunction. Our finding of an independent association between LV enddiastolic volume and MW-LGE supports the concept of a primary association between chamber remodeling and myocardial tissue damage manifested as MW-LGE.
Several possible mechanisms may explain our observed link between MW-LGE and LV chamber dilation. First, it is possible that increased chamber size, with concomitant increased wall stress as well as elevation of LV diastolic pressure impairs myocardial perfusion, resulting in localized myocardial ischemia or necrosis. Second, MW-LGE may reflect a localized manifestation of remodeling-associated alterations in systemic signaling pathways that serve to up-regulate expression of pro-fibrotic mediators. Indeed, patients with advanced LV dysfunction have been shown to manifest up-regulation of matrix metalloproteinases [30, 31] , which can contribute to extracellular matrix degradation and fibrosis [32] . On the other hand, it is conceivable that MW-LGE itself reflects a cause rather than a consequence of LV remodeling, whereby fibrosis contributes to altered myocyte mechanics and contributes to secondary chamber enlargement.
To the best of our knowledge, no prior study has examined whether LV remodeling is altered in proportion to actual extent of MW-LGE. Despite our finding that presence of MW-LGE was associated with increased chamber size, results demonstrated no significant relationship between the extent of MW-LGE and chamber size. It is possible that our observed lack of correlation reflects a physiologic phenomenon, whereby MW-LGE develops when a given threshold of chamber dilation has been achieved, but does not vary in relation to progressive chamber enlargement. It is also plausible that different pharmacologic interventions may variably attenuate LV volume overload or MW-LGE, thereby blunting the correlation between the two indices. Further studies, employing serial CMR to examine time dependent changes in MW-LGE and LV remodeling, as well as the impact of therapeutic interventions, are needed to test these concepts.
In conclusion, this study demonstrates that MW-LGE, while far more common in NICM, can occur in ICM and is a marker of LV chamber dilation irrespective of cardiomyopathic etiology.
Study limitations
Several limitations should be noted. First, whereas the interval between CMR and BP measurement was short (mean 4.7 ± 7.0 h), both LV volume and afterload status can vary on a near instantaneous basis. However, interval between CMR and BP did not differ between patients with and without MW-LGE (5.5 ± 8.3 vs. 4.6 ± 6.9 h, p = 0.49), supporting the notion that our observed association between MW-LGE and LV chamber enlargement was not influenced by this potential source of bias. Second, current analysis was limited to patients with LV systolic dysfunction, in context of recent data demonstrating MW-LGE to predict clinical prognosis in patients with systolic heart failure [14, 16] . While the results of the current study do not directly apply to MW-LGE in the absence of LV dysfunction, it is interesting to note that MW-LGE has been associated with right ventricular dilation among patients with pulmonary hypertension [33] , suggesting that CMR-evidenced alterations in septal tissue characteristics may be a more generalized marker of myocardial tissue substrate changes that accompany chamber remodeling. Lastly, as demographic data including prior history of MI were obtained via a standardized patient survey, the exact date of MI could not be verified in a number of patients. Due to this limitation, temporal relationships between prior MI and MW-LGE formation could not be assessed.
